hVIVO’s (HVO) “Buy” Rating Reiterated at Shore Capital Group

Shore Capital Group restated their buy rating on shares of hVIVO (LON:HVO) in a research note released on Wednesday morning, Marketbeat Ratings reports.

Separately, Stifel Nicolaus reiterated a “hold” rating and issued a GBX 10 target price on shares of hVIVO in a report on Wednesday, April 15th. Two investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of GBX 15.

hVIVO Stock Performance

LON:HVO opened at GBX 7.75 on Wednesday. hVIVO has a 12-month low of GBX 4.31 and a 12-month high of GBX 19.50. The company has a quick ratio of 1.16, a current ratio of 1.63 and a debt-to-equity ratio of 38.75. The firm has a market capitalization of £53.35 million, a PE ratio of 10.06 and a beta of 1.67. The firm has a 50-day moving average price of GBX 7.94 and a 200 day moving average price of GBX 6.88.

hVIVO (LON:HVO) last released its quarterly earnings results on Wednesday, April 15th. The company reported GBX (0.87) EPS for the quarter. hVIVO had a negative net margin of 12.48% and a negative return on equity of 14.65%. The company had revenue of GBX 4,677 million for the quarter. Research analysts anticipate that hVIVO will post 1.5492958 earnings per share for the current fiscal year.

Insider Activity at hVIVO

In related news, insider Brendan Buckley sold 2,017,000 shares of hVIVO stock in a transaction that occurred on Friday, April 24th. The shares were sold at an average price of GBX 9, for a total transaction of £181,530. Insiders own 5.24% of the company’s stock.

hVIVO Company Profile

hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model. In addition, the company is developing a database of infectious disease progression data that include Disease in Motion platform, which comprises unique datasets, such as clinical, immunological, virological, and digital (wearable) biomarkers.